Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020; 12(12): 615-625 [PMID: 33391614 DOI: 10.4330/wjc.v12.i12.615]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020; 12(12): 615-625 [PMID: 33391614 DOI: 10.4330/wjc.v12.i12.615]
Author contributions: Vani P, Patel A, and Salgotra V designed the study; Trimukhe R was involved in data collection, analysis and interpretation; all authors were involved in drafting, reviewing and approved the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by an Independent Ethics Committee.
Informed consent statement: The study involved retrospective data collection from the medical records in the hospital; therefore, we obtained permission from the head of the institution for data collection.
Conflict-of-interest statement: Vani P, Patel A, Salgotra V are employees of Sahajanand Laser Technology Ltd., and Dr. Trimukhe R is an employee of Atma Malik Hospital. The authors do not have any other conflicts of interest to declare.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Received: June 18, 2020 Peer-review started: June 18, 2020 First decision: September 18, 2020 Revised: October 15, 2020 Accepted: November 5, 2020 Article in press: November 5, 2020 Published online: December 26, 2020 Processing time: 182 Days and 0.9 Hours
Core Tip
Core Tip: New-generation drug-eluting stents (DES) reduce the risk of stent thrombosis. However, the everolimus-eluting coronary stent system (EES) exerts higher interaction with rapamycin complex 2, higher bioavailability, shorter half-life than sirolimus, decreases vascular inflammation and promotes rapid endothelialization; therefore, outperforms paclitaxel DES in safety and efficacy. EverProTM, a second-generation EES with a biodegradable polymer and a 60 μm cobalt-chromium platform design, facilitates reduction in intra-arterial injury. This observational study enrolled 77 patients with coronary artery disease (CAD), implanted with the EverProTM stent who completed a 1-year follow-up period after the index procedure. Our findings suggested that EverProTM EES is safe and effective with no major adverse cardiac events/stent thrombosis during the 1 year follow-up period in patients with CAD.
